These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15083480)

  • 1. Subject allocation and study curtailment for fixed event comparative Poisson trials.
    Hoover DR
    Stat Med; 2004 Apr; 23(8):1229-45. PubMed ID: 15083480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review.
    Sahai H; Khurshid A
    Stat Med; 1996 Jan; 15(1):1-21. PubMed ID: 8614740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allocation of subjects to test null relative risks smaller than one.
    Hoover DR; Blackwelder WC
    Stat Med; 2001 Oct; 20(20):3071-82. PubMed ID: 11590633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for count data in comparative clinical trials with nonuniform patient accrual and early dropout.
    Li H; Wang L; Wei L; Quan H
    J Biopharm Stat; 2015; 25(1):1-15. PubMed ID: 24836982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal design of clinical trials comparing several treatments with a control.
    Marschner IC
    Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
    Fay MP; Huang CY; Twum-Danso NA
    Clin Trials; 2007; 4(6):598-610. PubMed ID: 18042569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of three antimicrobial drugs protocol (Ceftriaxone, Gentamicin/Amikacin and Metronidazole) versus two antimicrobial drugs protocol (Ceftriaxone and Metronidazole) in cases of intra-abdominal sepsis.
    Khan S; Gupta DK; Khan DN
    Kathmandu Univ Med J (KUMJ); 2005; 3(1):55-63. PubMed ID: 16401946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential boundaries approach in clinical trials with unequal allocation ratios.
    Jafari P; Ayatollahi SM; Behboodian J
    BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculations for comparative clinical trials with over-dispersed Poisson process data.
    Matsui S
    Stat Med; 2005 May; 24(9):1339-56. PubMed ID: 15568188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a mis-specification of the response rate under standard treatment in sequential clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2005 Oct; 19(5):569-78. PubMed ID: 16176336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.